v3.20.1

Total revenues and other income - Allocation of transaction price (Details) € in Thousands, $ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 14, 2019 USD ($) | Jul. 14, 2019 EUR (€) | Jul. 14, 2019 EUR (€) Program item | Jul. 31, 2018 EUR (€) | Dec. 31, 2019 EUR (€) item
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Upfront received | $ 3,950 | € 3,569,800 |  |  |
Estimated significant financing component |  |  |  |  | € 44,500
Drug discovery platform revenue period |  |  |  |  | 10 years
Global research and development collaboration term |  |  | 10 years |  |
Number of molecules | item |  |  | 6 |  |
Number of preclinical programs | Program |  |  | 20 |  |
Period over which to recognize the drug discovery platform revenue |  |  |  |  | 10 years
Maximum extension period for specific program |  |  |  |  | 3 years
Filgotinib additional consideration |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Number of performance obligations exceeding one year | item |  |  |  |  | 1
Subsequent warrant B |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Total transaction price |  |  |  |  | € (16,184)
Novartis |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Upfront received |  |  |  | € 95,000 |
Gilead |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Upfront received |  |  |  |  | 3,569,815
Impact initial valuation of share subscription |  |  |  |  | 85,601
Total transaction price |  |  |  |  | 3,655,416
Allocation to performance obligations |  |  |  |  | € 3,593,376
Number of performance obligations exceeding one year | item |  |  |  |  | 2
Period recognized to consideration paid for the platform |  |  |  |  | 10 years
Gilead | Warrant A |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Total transaction price |  |  |  |  | € (43,311)
Gilead | Initial Warrant B |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Total transaction price |  |  |  |  | (2,545)
Gilead | Subsequent warrant B |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Total transaction price |  |  |  |  | (16,184)
Gilead | GLPG1690 |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Allocation to performance obligations |  |  |  |  | 666,967
Gilead | Filgotinib additional consideration |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Allocation to performance obligations |  |  |  |  | 641,663
Gilead | Drug discovery platform (10 years) |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Allocation to performance obligations |  |  |  |  | € 2,284,747
Gilead | Derivative financial instrument |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Number of performance obligations exceeding one year | item |  |  |  |  | 3
Offsetting short term financial asset (derivative) |  | € 85,600 | € 85,600 |  |

X
- Definition The amount consideration in the form of initial valuation of share subscription. + References No definition available. + Details
Name: | glpg_CollaborationAgreementConsiderationAsShareSubscription
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of estimated significant financing component reflecting the time value of money on the estimated recognition period. + References No definition available. + Details
Name: | glpg_CollaborationAgreementEstimatedSignificantFinancingComponentValue
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total transaction price under collaboration agreement. + References No definition available. + Details
Name: | glpg_CollaborationAgreementTotalTransactionPrice
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period over which the company can recognize the drug discovery platform revenue. + References No definition available. + Details
Name: | glpg_DrugDiscoveryPlatformRevenuePeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of contract for global research and collaboration. + References No definition available. + Details
Name: | glpg_GlobalResearchAndDevelopmentCollaborationTerm
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum extension period for specific program. + References No definition available. + Details
Name: | glpg_MaximumExtensionPeriodForSpecificProgram
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of molecules having right to access by the other party due to collaboration agreement. + References No definition available. + Details
Name: | glpg_NumberOfMoleculesHavingAccessToOtherParty
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of performance obligations over a period of more than one year. + References No definition available. + Details
Name: | glpg_NumberOfPerformanceObligation
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of preclinical program having right to access by the other party due to collaboration agreement. + References No definition available. + Details
Name: | glpg_NumberOfPreclinicalProgramsHavingAccessToOtherParty
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period over which the drug discovery program revenue will be recognized. + References No definition available. + Details
Name: | glpg_PeriodOverWhichDrugDiscoveryProgramRevenueIsRecognized
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period recognized to consideration paid for platform. + References No definition available. + Details
Name: | glpg_PeriodRecognizedToConsiderationPaidForPlatform
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payments, license fees, and milestones received + References No definition available. + Details
Name: | glpg_UpfrontPaymentsLicenseFeesAndMilestonesReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The gross amount of recognised financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2019-01-01 -Paragraph 13C -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2019-en-r&anchor=para_13C_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 120 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_120_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_SecondCollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_SubsequentWarrantBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=glpg_WarrantIssuanceLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=glpg_InitialWarrantBIssuanceLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=glpg_SubsequentWarrantBIssuanceLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForGLPG1690Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_DerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |